A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)
Details
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Prem Subramanian, MD, PhD
Study ID
Protocol Number: 21-4929
More information available at ClinicalTrials.gov: NCT05176639
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers